New treatments face many challenges. Apart from the lack of clinical experience, patient cohorts can vary considerably in how they respond to new modalities, decreasing confidence to prescribe. Educating clinicians on patient cohort experience in a peer-to-peer environment can make a big difference. Learn how MedShr has helped through disease awareness campaigns.
Once regulatory approval is given for a new treatment, decades of hard work is about to make a difference in patients’ lives. The bridge between approval and market adoption can be short or long. Reaching busy clinicians is paramount whatever the treatment modality. MedShr has shortened adoption timelines through case-based education and targeted discussion groups. Read more.
Case discussions engage doctors in active knowledge sharing and show how to apply learning to clinical practice. More than 90 per cent of case discussions on MedShr are user generated and 40,000 new clinical members are joining MedShr each month. See how MedShr has enabled its active communities to increased knowledge around a particular therapeutic area.
MedShr enables medical societies to better reach, engage and educate their members. We have over 200 partnerships with medical societies, including the American College of Cardiology, the Muscular Dystrophy Association and the British Society for Medical Dermatology. Find out more about our partners around the world.
Sharing of expertise is crucial to support progress in disease management, especially for rare conditions. Yet the world of medical specialists is more global and disbursed than ever. MedShr can help to reach a global community of focused specialists in rare disease. Learn about our expertise in rare disease.
Online medical education often fails to reach HCPs in the difficult-to-penetrate markets of the global south. MedShr has award-winning expertise expertise in reaching doctors and community health workers, particularly those working in resource-scarce settings to build skills and capacity.